Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 234,943,569 papers from all fields of science
Search
Sign In
Create Free Account
rolapitant
Known as:
1,7-diazaspiro(4.5)decan-2-one, 8-(((1R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)methyl)-8-phenyl-, (5S,8S)-
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
4 relations
Breast Cancer Resistance Protein Inhibitors [MoA]
rolapitant 90 MG Oral Tablet [Varubi]
rolapitant hydrochloride
Narrower (1)
Varubi
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
AN EXTENSIVE REVIEW ON CHEMOTHERAPY INDUCED NAUSEA AND VOMITING
P. Bhulakshmi
,
G. Nagaraju
,
K. Srilaya
Journal of Drug Delivery and Therapeutics
2018
Corpus ID: 81917866
Chemotherapy induced nausea and vomiting is the among most feared and debilitating adverse events experienced by the cancer…
Expand
2018
2018
Abstract P6-11-18: Ten year trends in antiemetic prescribing in cancer patients receiving highly emetogenic chemotherapy (HEC)
C. O'Sullivan
,
H. V. Houten
,
+6 authors
K. Ruddy
2018
Corpus ID: 80586216
Purpose: Prevention of chemotherapy-induced nausea and vomiting (CINV) is essential to preserve quality of life in cancer…
Expand
2017
2017
FDA Approves Rolapitant for Delayed CINV
B. Furlow
2017
Corpus ID: 182122616
The FDA has approved rolapitant injectable emulsion in combination with other antiemetics in adults to prevent delayed…
Expand
2017
2017
Method for synthesizing rolapitant intermediate
袁伟
,
张翔
,
+5 authors
杜伟
2017
Corpus ID: 139363011
The invention discloses a method for synthesizing a rolapitant intermediate. The method comprises a recrystallization method for…
Expand
Review
2017
Review
2017
Is Rolapitant Effective in Reducing the Incidence of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients Receiving Emetogenic Chemotherapy?
Brandon E Eberts
2017
Corpus ID: 86811944
Objective: The objective of this selective EBM review is to determine whether or not rolapitant is safe and effective in reducing…
Expand
Review
2017
Review
2017
Injectable Emulsion Admixed with Intravenous Palonosetron Hydrochloride
George Wu
,
S. Yeung
,
PharmD Frank Chen
2017
Corpus ID: 4127772
Neurokinin-1 receptor antagonist, 5-hydroxytryptamine-3 RA, and dexamethasone combination therapy is standard of care for the…
Expand
2017
2017
Rolapitant-Based Antiemetic Combination Improves CINV Symptoms
B. Furlow
2017
Corpus ID: 217078494
Rolapitant plus 5-HT3 receptor antagonist and dexamethasone is well tolerated and more effectively controls chemotherapy-induced…
Expand
2016
2016
Erratum: Efficacy of the neurokinin‐1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin‐based chemotherapy
Cancer
2016
Corpus ID: 52308888
Review
2014
Review
2014
New data in emerging treatment options for chemotherapy-induced nausea and vomiting in clinical practice: general discussion.
Rugo Hs
,
N. Rm
Clinical advances in hematology & oncology : H&O
2014
Corpus ID: 37123376
Chemotherapy-induced nausea and vomiting (CINV) has long been one of the most troublesome adverse effects of chemotherapy…
Expand
2014
2014
LBA47_PRPHASE 3 (P04832) TRIAL RESULTS FOR ROLAPITANT, A NOVEL NK-1 RECEPTOR ANTAGONIST, IN THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) IN PATIENTS RECEIVING CISPLATIN-BASED…
M. Chasen
,
A. Poma
,
M. Hedley
,
R. Martell
,
C. Gridelli
2014
Corpus ID: 73105288
ABSTRACT Aim: Rolapitant is a highly selective competitive long acting NK-1 receptor antagonist that demonstrated safety and…
Expand